Pfizer (NYSE: PFE) EVP Guegan reports 149K shares, SARs
Rhea-AI Filing Summary
PFIZER INC (PFE) reported the initial holdings of Executive Vice President Cecile Guegan on a Form 3. She directly owns 149,505 shares of Pfizer common stock. She also holds multiple Stock Appreciation Rights (SARs) over Pfizer common stock, including SARs with exercise prices of $25.75 on 33,051 underlying shares expiring on March 4, 2030, and SARs with exercise prices of $26.58, $26.89, $31.31, $33.82, $42.30 and $45.96 over various numbers of underlying shares, expiring between 2027 and 2031. Footnotes state these SARs are subject to vesting and will be settled in Pfizer common stock on either the fifth or seventh anniversary of the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
11 transactions reported
Mixed
11 txns
Insider
Guegan Cecile
Role
Executive Vice President
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Appreciation Rights F1 | -- | -- | -- |
| holding | Stock Appreciation Rights F1 | -- | -- | -- |
| holding | Stock Appreciation Rights F1 | -- | -- | -- |
| holding | Stock Appreciation Rights F2 | -- | -- | -- |
| holding | Stock Appreciation Rights F2 | -- | -- | -- |
| holding | Stock Appreciation Rights F2 | -- | -- | -- |
| holding | Stock Appreciation Rights F2 | -- | -- | -- |
| holding | Stock Appreciation Rights F2 | -- | -- | -- |
| holding | Stock Appreciation Rights F2 | -- | -- | -- |
| holding | Stock Appreciation Rights F2 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Appreciation Rights — 123,959 shares (Direct);
Common Stock — 149,505 shares (Direct)
Footnotes (2)
- F1. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
- F2. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.
Key Figures
Directly owned common stock: 149,505 shares
SAR exercise price: $25.75
Underlying shares for SARs at $25.75: 33,051 shares
+5 more
8 metrics
Directly owned common stock
149,505 shares
Common stock beneficially owned directly by Cecile Guegan
SAR exercise price
$25.75
Stock Appreciation Rights over 33,051 underlying shares expiring March 4, 2030
Underlying shares for SARs at $25.75
33,051 shares
Common stock underlying Stock Appreciation Rights with a $25.75 exercise price
SAR exercise price
$26.58
Stock Appreciation Rights over 15,748 underlying shares expiring March 3, 2031
Underlying shares for SARs at $26.58
15,748 shares
Common stock underlying Stock Appreciation Rights with a $26.58 exercise price
SAR exercise price
$26.89
Stock Appreciation Rights over 13,430 underlying shares expiring February 27, 2029
Underlying shares for SARs at $26.89
13,430 shares
Common stock underlying Stock Appreciation Rights with a $26.89 exercise price
SAR latest expiration
2031-03-03
Expiration date of one SAR grant with a $26.58 exercise price
Key Terms
Stock Appreciation Rights, underlying security, exercise price, expiration date, +1 more
5 terms
Stock Appreciation Rights financial
"The stock appreciation rights, which are subject to certain vesting requirements"
Stock appreciation rights (SARs) are a form of employee compensation that give the holder the right to receive the increase in a company's stock price over a set baseline, paid in cash or shares, without having to buy the stock. For investors, SARs matter because they can create future cash outflows or share dilution and signal how a company rewards and motivates executives — similar to giving a bonus tied directly to how well the company’s stock performs.
underlying security financial
"underlying_security_title": "Common Stock""
exercise price financial
"conversion_or_exercise_price": "25.7500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2030-03-04""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
beneficial ownership financial
"initial statement of beneficial ownership of securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What does Pfizer (PFE) disclose about Cecile Guegan’s common stock holdings in this Form 3?
The filing reports that Executive Vice President Cecile Guegan directly owns 149,505 shares of Pfizer common stock as of the reported date. This reflects her beneficial ownership position but does not indicate any recent purchase or sale transactions.
How will Cecile Guegan’s Pfizer (PFE) SARs be settled?
According to the footnotes, the stock appreciation rights, which are subject to vesting requirements, will be settled in shares of Pfizer common stock on either the fifth or seventh anniversary of the date of grant, depending on the specific SAR grant.
Do the reported SARs for PFE have different exercise prices and maturities?
Yes. The filing lists SARs with exercise prices of $25.75, $26.58, $26.89, $31.31, $33.82, $42.30, and $45.96, each tied to specified numbers of underlying shares and expiring on dates ranging from 2027 through 2031.
Does this Pfizer (PFE) Form 3 show any insider buying or selling by Cecile Guegan?
No. The entries are categorized as holdings, and the transaction summary shows no buy or sell transactions. The Form 3 serves as an initial statement of beneficial ownership, listing existing common stock and SAR positions rather than new trades.
AI-generated analysis. How Rhea-AI works. Not financial advice.
